Why Making the Drug Is Only Half the Battle

What does it actually take to turn a scientific breakthrough into a drug patients can access?In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure.This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time.Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value.Timestamps00:00 Intro: The Drug Exists. Access Still Breaks Down05:44 FDA Approval Is Not the Finish Line09:41 Inside the R&D Risk Machine13:24 Why Most Drug Trials Fail15:32 The Patent Clock Starts Early24:39 Why U.S. Drug Prices Run Higher29:19 The Gross-to-Net Bubble40:16 The Pharma Paradox44:05 The IRA Changes the Game50:59 Invention Is Not Enough